GRI
GRI Bio files corporate presentation highlighting strategy for inflammatory diseases
GRI Bio filed a business update as of Sept. 2026 outlining its efforts to address inflammatory diseases despite current resource constraints.
GRI news
Latest 2 stories · newest Sep 8, 2026
GRI
GRI Bio Receives FDA Orphan Drug Designation for GRI-0621 in IPF
GRI Bio announced FDA Orphan Drug Designation for GRI-0621 (Tazarotene) to treat Idiopathic Pulmonary Fibrosis, a rare progressive lung disease. The designation provides potential seven-year U.S. market exclusivity, tax credits, and regulatory benefits that could accelerate development and create si…
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same GRI feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/GRI/newsSTART FREE